BioNTech Announces Major Investment in Oncology Research and Positive Results from Cancer Drug Candidate
Second Phase 2 Trial Initiated for Company's Individualized mRNA-Based Cancer Vaccine Platform
MAINZ, Germany, October 19, 2023 (GLOBE NEWSWIRE)
BioNTech SE (Nasdaq: BNTX) today announced that it will intensify its oncology research with billion-dollar investments and has initiated the second Phase 2 trial for its proprietary individualized mRNA-based cancer vaccine platform, iNeST.
The company's COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 has shown significant improvement in the three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran.
Comments